Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
- PRE-REGISTRATION ELIGIBILITY
- Post-menopausal defined as * Age >= 60 and amenorrhea > 12 consecutive months OR * Previous bilateral oophorectomy OR * Age < 60 and amenorrhea > 12 consecutive months and documented follicle stimulating hormone (FSH) level within post-menopausal range according to institutional standard * NOTE: If FSH level not within post-menopausal range according to institutional standard, but there is other evidence of post-menopausal status, exceptions may be granted by the principal investigator (PI)
- Histologic proof of metastatic or locally advanced, unresectable breast cancer
- History of ER positive (+) (>= 10% of cells positive on hematoxylin and eosin stain [H&E]), HER2 negative (−) breast cancer disease, either as a * History of primary, operable ER+/HER2− invasive breast cancer OR * History of de novo metastatic breast cancer that is ER+/HER2− ** Note: HER2− (negative) disease defined as one of the following: *** HER2 immunohistochemistry (IHC) expression of 0, 1+ and in-situ hybridization (ISH) non-amplified *** HER2 IHC expression of 0, 1+ and ISH not done *** HER2 IHC expression of 2+ and ISH non-amplified *** IHC not done and ISH non-amplified; Note: supporting documentation such as a pathology report from their primary diagnosis that indicates ER+/Her2- invasive breast cancer or a biopsy report of de novo metastatic breast cancer that is ER+/HER2− should be submitted through the RAVE database
- Prior treatment * No more than two prior chemotherapy regimens in the metastatic setting * Prior treatment with fulvestrant in the metastatic setting is required, except for patients with a history of ER-negative metastatic breast cancer * Unlimited prior endocrine therapy regimens in the metastatic setting are allowed * No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)
- Disease that is measurable where: * A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) * A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible
- No history of tumors involving spinal cord or heart
- Fully recovered from acute, reversible effects of prior therapy regardless of interval since last treatment * EXCEPTION: neuropathies – if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment patient is eligible
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1
- No requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes
- Willing to limit daily alcohol intake to the following: one 12-oz glass of beer, one 6-oz glass of wine, or one 1.5-oz portion of 80-proof alcohol
- No uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Uncontrolled symptomatic cardiac arrhythmia * Uncontrolled hypertension (defined as blood pressure > 160/90)
- No history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease, or requirement for supplemental oxygen
- No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration * NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registration
- Ability to provide written informed consent
- Willing to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institution
- No history of myocardial infarction =< 6 months prior to pre-registration or New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- No prior allogeneic bone marrow or organ transplantation
- No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
- No co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Able to swallow oral medication
- No known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease
- No visceral crisis: Visceral crisis is moderate-to severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease
- Willing to undergo a biopsy of a metastatic site of breast disease for central laboratory determination of ER and correlative research purposes * NOTE: If insufficient or no tissue is obtained by the pre-registration biopsy, an archival tissue specimen (preferably from a metastatic site) must be available to submit for Central Laboratory ER determination prior to registration
- REGISTRATION ELIGIBILITY CRITERIA
- =< 28 days post pre-registration
- Central Laboratory ER determination completed
- Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to randomization)
- Platelet count >= 100,000/mm^3 (obtained =< 14 days prior to randomization)
- Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to randomization)
- Total bilirubin =< upper limit of normal (ULN) (obtained =< 14 days prior to randomization) * NOTE: If total bilirubin is out of range then direct bilirubin must be =< ULN
- Alanine transaminase (ALT) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =< 14 days prior to randomization)
- Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula (obtained =< 14 days prior to randomization)
- ECOG performance status: 0 or 1
- Life expectancy of >= 6 months
- Willing to provide blood and tissue for correlative research purposes
- REGISTRATION EXCLUSION CRITERIA
- Any of the following therapies prior to registration: * Chemotherapy =< 21 days * Immunotherapy =< 21 days * Biologic therapy (includes monoclonal antibodies) =< 21 days * Hormonal therapy =< 14 days except fulvestrant =< 21 days * Targeted therapies including CDK 4/6 inhibitors (e.g. palbociclib, abemaciclib, ribociclib, etc.) and mTOR inhibitors (e.g. everolimus) =< 21 days * Other investigational agents =< 21 days * Radiation therapy =< 14 days * Minor surgical or interventional procedure =< 7 days • Major surgical procedure =< 21 days
- Administration of myeloid growth factors or platelet transfusion =< 14 days prior to registration
- Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration
- Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort =< 14 days prior to registration
- Require constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes
- Development of visceral crisis since pre-registration. * NOTE: Visceral crisis is moderate-to-severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease.
- History of brain metastases
District of Columbia
I. To assess the impact on objective tumor response rate (using Response Evaluation Criteria in Solid Tumors [RECIST] criteria) with the addition of fulvestrant to alisertib in women with endocrine resistant, advanced estrogen receptor positive breast cancer.
I. To evaluate the safety profile of each treatment regimen.
II. To assess the impact on median progression-free survival with the addition of fulvestrant to alisertib.
III. To obtain estimated tumor response rate and the median progression-free survival time during alisertib and fulvestrant treatment in the cohort of patients who progress during alisertib monotherapy, and crossover to receive the combination of alisertib and fulvestrant.
I. To assess the changes in aurora A kinase, SMAD5 and SOX2 expression and phosphorylation in tumor tissue after first cycle of assigned treatment.
II. To assess the changes in estrogen receptor (ER) expression and function in tumor tissue after the first cycle of assigned treatment.
I. To generate patient derived xenografts (PDX) from tumors collected at baseline and progression of disease (PD) in order to identify mechanisms associated with both de novo and acquired alisertib resistance.
II. After the first cycle of treatment, to assess changes in aurora A kinase, phosphorylated (p)~SOX2 and ER expression on circulating tumor cells (CTCs), and to assess concordance between change in expression with tumor tissue and CTCs.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive alisertib orally (PO) twice daily (BID) on days 1-3, 8-10, and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
ARM II: Patients receive fulvestrant intramuscularly (IM) over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 of all subsequent cycles. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for up to 5 years.
Trial Phase Phase II
Trial Type Treatment
Mayo Clinic in Rochester
Tufia Christine Haddad
- Primary ID MC1431
- Secondary IDs NCI-2016-01211
- Clinicaltrials.gov ID NCT02860000